Merrill Lynch Selects Sybari's Antigen for Antivirus Protection

Business Wire, Sept 5, 2000

Business & Technology Editors

E. NORTHPORT, N.Y.--(BUSINESS WIRE)--Sept. 5, 2000

Sybari Software, Inc., the premier antivirus and security specialist for groupware solutions, today announced that Merrill Lynch (NYSE: MER) has selected Sybari's Antigen to provide antivirus protection for its global groupware environment.

"With one of the largest Microsoft Exchange environments deployed on a global scale, we required an antivirus solution that could deliver comprehensive security and protection in a complex groupware environment," said Kimberly Scott, vice president, Email Product Management, Merrill Lynch. "We subjected Antigen to rigorous testing and in every case Antigen reliably scanned 100% of the messages before objects were written to the information store, with little or no adverse impact on server performance.

Antigen's innovative management of the scanning process provides Microsoft Exchange and Lotus Notes users with the most comprehensive protection available against the threat of destructive viruses. Antigen integrates with groupware as a multi-faceted antivirus solution, scanning and managing incoming e-mail and data before these can reach sensitive parts of the network. Through its unique processes of in-memory scanning, which scans objects as these are written to the information store in real time, and trusted scanning, which allows messages scanned at one location to pass as trusted to the next, Antigen significantly reduces the burden the antivirus solution imposes on network resources.

"Each Antigen deployment has its own considerations and challenges," said Joseph King, director of technical support for Sybari Software, Inc. "Our support technicians are groupware specialists, who understand a client's needs as these pertain to the complex and demanding groupware environment. Antigen has been designed to optimize groupware performance while providing the highest degree of protection for the enterprise. It is this expertise that has allowed Sybari to establish itself as the premier provider of security for the Exchange and Notes environments."

"We are pleased that Merrill Lynch has selected Antigen to protect its global groupware environment," said Robert Wallace, president and CEO of Sybari Software. "Merrill Lynch joins other industry leaders who have selected Antigen as a proven solution."

ABOUT ANTIGEN

Antigen for Exchange and Notes is currently shipping. Antigen is available as a two-year renewable license based on the number of users protected within an organization. Pricing is discounted by volume with a per user range of $25-$10 per user. Sybari offers additional pricing and support options as "trade-up" pricing for products from vendors such as Network Associates (NASDAQ:NETA), Symantec (NASDAQ:SYMC) and Trend Micro (NASDAQ:TMIC). For more information on Antigen and its more complex features, please visit the Sybari website at http://www.sybari.com or send an email to info@sybari.com.

ABOUT SYBARI

Since 1995, Sybari has been investigating and providing solutions for groupware-based viruses and security threats. Today, over four million groupware seats are virus-free as a result of Sybari's Antigen technology. Sybari produces Antigen for Notes and Antigen for Exchange, which is distributed in more than 50 countries through their worldwide offices and distribution network. Sybari is headquartered in E.Northport, New York with its International headquarters in Madrid, Spain. Sybari's clients include IBM, Dell, Compaq, ABB, JD Power, Amazon, Nortel, Visa, Tosco, Lufthansa, US Federal Government, Union Pacific, Wang Global/Getronics and Texaco. Evaluation copies of Antigen for Notes or Exchange are available for download from the Sybari Web site--http://www.sybari.com. Sybari's many strategic partners include Lotus Development (NYSE:IBM), Microsoft (Nasdaq:MSFT), Computer Associates (NYSE:CA), Compaq (NYSE:CPQ) and Sun Microsystems (Nasdaq:SUNW).

Other products and company names mentioned herein may be trademarks of their respective owners.